This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A near infrared fluorescent contrast agent comprising a compound represented by of the following formula [I] or a pharmaceutically acceptable salt thereof:

wherein R^1 , R^2 , R^7 , and R^8 independently represent a substituted or unsubstituted C_1 - C_{10} alkyl group or a substituted or unsubstituted aryl group, and or R^1 and R^2 and/or R^7 and R^8 may bind to each other to form a ring; R^3 , R^4 , R^5 , R^6 , R^9 , R^{10} , R^{11} and R^{12} independently represent a hydrogen atom, a substituted or unsubstituted C_1 - C_6 alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a halogen atom, cyano group, carboxyl group, or sulfo group, and or R^3 ,

 R^4 , R^5 , R^6 , R^9 , R^{10} , R^{11} , and R^{12} may bind to each other to form a ring; X^4 and X^2

independently represents a substituted or unsubstituted C_1 - C_{15} alkyl group or a substituted or unsubstituted aryl group and X^1 and X^2 in total have 0 to 4 carboxyl groups, provided that when the number of the carboxyl group is 0 or 1, each of X^4 and X^2 is a C_1 - C_5 carboxyalkyl group or a sulfoalkyl group and at least one of R^3 , R^4 , R^5 , R^6 , R^9 , R^{10} , R^{11} , and R^{12} represents a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group; is a group represented by the following formula



wherein Y^1 and Y^2 independently represent a substituted or unsubstituted divalent linking group and X^1 and X^2 in total have 2 or 4 carboxyl groups; m^1 represents 0 or 1; m^2 represents 0 or 1; m^3 represents 0 or 1; m^4 represents a hydrogen substituted methine group, provided that when two or more of the methine group substituted hydrocarbon group and m^4 represents of m^4 and m^4 represents a hydrogen atom, a metal, or a quaternary ammonium salt; and n represents an integer of 1 to 7 necessary for neutralizing charge

and a pharmaceutically acceptable carrier for diagnostic imaging.

- 2. (Original) The near infrared fluorescent contrast agent according to claim 1, wherein each of m^1 , m^2 , and m^3 is 1.
 - 3. (Canceled)
- 4. (Currently Amended) The near infrared fluorescent contrast agent according to claim 1, wherein X^1 and X^2 independently represent a group represented by the following formula (i):

wherein Y^1 and Y^2 independently represent a substituted or unsubstituted a divalent bond.

- 5. (Original) The near infrared fluorescent contrast agent according to Claim 1, wherein at least one of R³, R⁴, R⁵, R⁶, R⁹, R¹⁰, R¹¹, and R¹² is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
 - 6. (Canceled)
 - 7. (Canceled)
- 8. (Original) The near infrared fluorescent contrast agent according to Claim 3 wherein Y_1 represents -(CH₂)_pCONH- wherein p represents an integer of 1 to 4 and Y_2 represents -(CH₂)-or (CH₂)₂-.
- 9. (Currently Amended) The near infrared fluorescent contrast agent according to Claim 1, which is used adapted for tumor imaging.
- 10. (Currently Amended) The near infrared fluorescent contrast agent according to Claim 1, which is used adapted for angiography.
- 11. (Currently Amended) A method of fluorescence imaging which comprises the steps of introducing the near infrared fluorescent contrast agent according to Claim 1 into a living body, exposing said body to an excitation light, and detecting near infrared fluorescence from the contrast agent.
 - 12. (New) A method of claim 11 for tumor imaging.
 - 13. (New) A method of claim 11 for angiography.